Embecta (EMBC) Competitors

Embecta (NASDAQ:EMBC) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations.

Does the MarketBeat Community favor EMBC or LIVN?

LivaNova received 407 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 69.80% of users gave LivaNova an outperform vote while only 9.52% of users gave Embecta an outperform vote.

Company	Underperform	Outperform
Embecta	Outperform Votes 2 9.52%	Underperform Votes 19 90.48%
LivaNova	Outperform Votes 409 69.80%	Underperform Votes 177 30.20%

Does the media prefer EMBC or LIVN?

In the previous week, LivaNova had 2 more articles in the media than Embecta. MarketBeat recorded 4 mentions for LivaNova and 2 mentions for Embecta. LivaNova's average media sentiment score of 0.90 beat Embecta's score of 0.45 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in EMBC or LIVN?

93.8% of Embecta shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 0.4% of Embecta shares are held by company insiders. Comparatively, 0.3% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has better valuation & earnings, EMBC or LIVN?

Embecta has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.54	$78.30M	$0.90	11.16
LivaNova	$1.28B	1.99	$17.55M	-$4.09	-11.40

Do analysts prefer EMBC or LIVN?

Embecta presently has a consensus target price of $19.33, suggesting a potential upside of 92.56%. LivaNova has a consensus target price of $59.29, suggesting a potential upside of 27.14%. Given Embecta's higher possible upside, equities analysts clearly believe Embecta is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
LivaNova	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is EMBC or LIVN more profitable?

Embecta has a net margin of 5.25% compared to LivaNova's net margin of 1.91%. LivaNova's return on equity of 13.81% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	5.25%	-19.22%	11.92%
LivaNova	1.91%	13.81%	7.07%

Which has more volatility & risk, EMBC or LIVN?

Embecta has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Summary

LivaNova beats Embecta on 12 of the 19 factors compared between the two stocks.